H.C. Wainwright analyst Ed Arce maintained a Buy rating on Madrigal Pharmaceuticals (NASDAQ:MDGL) Inc on Friday, setting a price target of $170, which is approximately 103.96% above the present share price of $83.35.
Arce expects Madrigal Pharmaceuticals Inc to post earnings per share (EPS) of -$3.79 for the fourth quarter of 2021.
The current consensus among 7 TipRanks analysts is for a Strong Buy rating of shares in Madrigal Pharmaceuticals, with an average price target of $170.29.
The analysts price targets range from a high of $220 to a low of $133.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $0 and a net profit of -$63.16 million. The company's market cap is $1.43 billion.
According to TipRanks.com, H.C. Wainwright analyst Ed Arce is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 16.7% and a 38.42% success rate.
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.